GlassScriptPhysician profile
Ellen R Scott
NPI 1831720481
$2,026.16
in general payments reported to CMS, 2019-2025
25 companies · $996 in 2025
The $996 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $139 · 2023: $257 · 2024: $634 · 2025: $996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,688 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,687.79 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $320.23 | 2023-2025 | Fruzaqla, Ninlaro, Alunbrig |
| Janssen Biotech, INC. | $253.99 | 2023-2025 | Rybrevant, Erleada, Akeega |
| Genzyme Corporation | $199.29 | 2023-2025 | |
| Celgene Corporation | $129.05 | 2024-2025 | Opdivo, Pomalyst, Reblozyl |
| Puma Biotechnology, INC. | $112.32 | 2024-2025 | |
| Daiichi Sankyo INC. | $112.11 | 2024-2025 | Enhertu |
| Merck Sharp & Dohme LLC | $109.56 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $99.57 | 2022-2025 | |
| Incyte Corporation | $92.40 | 2024-2025 | Jakafi, Niktimvo, Monjuvi |
| Astrazeneca Pharmaceuticals LP | $81.06 | 2024-2025 | Tagrisso |
| Glaxosmithkline, LLC. | $79.92 | 2022-2025 | Ojjaara |
| Abbvie INC. | $60.95 | 2025 | |
| Eisai INC. | $59.28 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $44.19 | 2025 | Libtayo |
| Lilly USA, LLC | $39.93 | 2025 | Jaypirca, Verzenio |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $38.42 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $37.68 | 2024 | |
| Genmab U.S., INC. | $25.55 | 2024 | Tivdak |
| Tempus Ai, INC | $23.68 | 2025 | Xt Cdx |
| Adaptive Biotechnologies Corporation | $23.31 | 2025 | Clonoseq |
| Sobi, INC | $20.48 | 2025 | |
| Array Biopharma INC | $18.83 | 2025 | Lorbrena, Mektovi, Braftovi |
| E.R. Squibb & Sons, L.L.C. | $15.99 | 2025 | Opdivo |
| Astellas Pharma US INC | $14.93 | 2025 | Xtandi |
| Genentech USA, INC. | $13.44 | 2023 | Alecensa, Phesgo, Tecentriq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.